Reuters logo
BRIEF-Tonix Pharmaceuticals' PTSD phase 3-ready drug candidate, TNX-102 SL, granted breakthrough therapy designation by FDA
December 19, 2016 / 12:18 PM / a year ago

BRIEF-Tonix Pharmaceuticals' PTSD phase 3-ready drug candidate, TNX-102 SL, granted breakthrough therapy designation by FDA

Dec 19 (Reuters) - Tonix Pharmaceuticals Holding Corp

* Prepare to initiate phase 3 honor study in q1 of 2017

* Tonix pharmaceuticals’ ptsd phase 3-ready drug candidate, tnx-102 sl, granted breakthrough therapy designation by the fda Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below